Related Experiment Video
Updated: Feb 12, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices
1Department of Medicine and Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract:
In patients with immune thrombocytopenia who do not adequately respond to first-line therapy, there is no clear consensus on which second-line therapy to initiate and when. This situation leads to suboptimal approaches, including prolonged exposure to treatments that are not intended for long-term use (eg, corticosteroids) and overuse of off-label therapies (eg, rituximab) while approved, more efficacious options exist. These approaches may not only fail to address symptoms and burden of disease, but may also worsen health-related quality of life. A better understanding of available second-line treatments may ensure best use of therapeutic options and thereby optimize patient outcomes.
Related Concept Videos
Phase Transitions
Properties of Transition Metals
Cooperative Allosteric Transitions
Phase Transitions: Vaporization and Condensation
Phase Transitions: Sublimation and Deposition
Phase Transitions: Melting and Freezing

